A ‘Darling’ Discovery: An Approach to Histoplasmosis and Blastomycosis

Histoplasmosis and blastomycosis are soil-dwelling fungal infections that, while often asymptomatic in immunocompetent hosts, can progress to severe pulmonary or disseminated disease. Inhalation of aerosolized microconidia leads to infection, where these organisms transition from mold to yeast within the body. Clinical diagnosis relies on identifying environmental exposures—such as construction, spelunking, or riverbank proximity—and distinguishing between the two based on specific manifestations; blastomycosis frequently presents with ulcerative skin lesions, whereas histoplasmosis may mimic tuberculosis or cause rheumatological symptoms. Management centers on antifungal therapy, primarily itraconazole and amphotericin B, with treatment duration and intensity dictated by disease severity and immune status. Recent clinical evidence suggests that a single dose of liposomal amphotericin B is non-inferior to traditional two-week regimens for treating disseminated histoplasmosis in advanced HIV patients, offering a promising strategy to improve care access.